Previous Close | 0.0600 |
Open | 0.0000 |
Bid | 0.0600 x N/A |
Ask | 0.0700 x N/A |
Day's Range | 0.0600 - 0.0600 |
52 Week Range | 0.0250 - 0.2900 |
Volume | |
Avg. Volume | 15,135 |
Market Cap | 2.809M |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.1000 |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Identification of a potent, monomolecular non-hallucinogenic analog of psilocybin 100 times stronger than psilocybin. Vancouver, British Columbia--(Newsfile Corp. - March 14, 2023) - MYND Life Sciences Inc. (CSE: MYND) (OTCQB: MYNDF) ("MYND" or the "Company"), a biopharmaceutical research and development company creating innovative precision medicines and diagnostic solutions for patients with relentless neurological diseases, announced that it has successfully accomplished a significant milesto
Vancouver, British Columbia--(Newsfile Corp. - March 1, 2023) - MYND Life Sciences Inc. (CSE: MYND) ("MYND" or the "Company") announces that it has been advised by its external auditors (the "Auditors") that they will not be in a position to complete their work on the Company's annual consolidated financial statements for the year ended October 31, 2022 (the "2022 Financial Statements") prior to the filing deadline of February 28, 2023 (the "Annual Filing Deadline"). ...
Vancouver, British Columbia--(Newsfile Corp. - February 9, 2023) - MYND Life Sciences Inc. (CSE: MYND) (OTCQB: MYNDF) ("MYND" or the "Company"), a biopharmaceutical research and development company creating innovated and precision medicines for patients with relentless neurological diseases, is pleased to announce the disposition of the Company's leasehold agreement at 733 Finns Road, Kelowna with tenant improvements and a Health Canada cannabis license for an aggregate $1,000,000. The 733 Finns